3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
pembrolizumab
23
Carboplatin
23
Paclitaxel
17
Specimen Handling
15
Magnetic Resonance Spectroscopy
11
Cyclophosphamide
10
Biopsy
10
Taxes
7
Capecitabine
7
Nivolumab
6
130-nm albumin-bound paclitaxel
6
sacituzumab govitecan
5
Gemcitabine
5
Doxorubicin
5
Albumin-Bound Paclitaxel
5
Fulvestrant
4
olaparib
3
fludarabine
3
eribulin
3
durvalumab
3
atezolizumab
3
Letrozole
3
Epirubicin
3
Bevacizumab
3
veliparib
2
poly ICLC
2
pertuzumab
2
aldesleukin
2
abemaciclib
2
Trastuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.